FOLH1 and prostate cancer: Recent experience in innovative imaging modalities, such as PET-prostate-specific membrane antigen (PSMA) in patients with prostate cancer, has led to the assumption that in some cases, nodal metastases could occur at sites beyond the typical locations mentioned in current contouring guidelines (29).